Composition

SHOTAPEN L.A. is a sterile, ready-to-use white suspension containing 73.58 mg of benzathine benzylpenicillin, 56.80 mg of procaine benzylpenicillin, and 164 mg of dihydrostreptomycin sulfate per 1 ml. It also contains sodium methyl parahydroxybenzoate and sodium propylparahydroxybenzoate as preservatives and sodium formaldehyde sulfoxylate as an antioxidant.

 

 

Pharmacological Properties

Pharmacodynamic Properties

Penicillin G is a time-dependent bactericidal antibiotic that works by blocking bacterial cell wall biosynthesis, affecting bacteria in the growth phase. Its spectrum of activity is limited to gram-positive bacteria and Pasteurella species.

Dihydrostreptomycin is a bactericidal antibiotic that works by disrupting bacterial protein biosynthesis and cell membrane permeability. Its spectrum of activity is predominantly directed against gram-negative bacteria.

The combination of these two antibiotics produces a synergistic effect in vitro. Penicillin enhances the penetration of dihydrostreptomycin into the bacterial cell. This combination provides complementary activity against gram-negative bacteria (Pasteurella, Histophilus, Actinobacillus), gram-positive bacteria (Staphylococcus spp., Streptococcus spp., Corynebacterium spp., anaerobic bacilli, Erysipelothrix spp.), and spirochetes.

 

Pharmacokinetic Properties
After parenteral administration, benzylpenicillin is slowly released due to its benzathine salt form, compared to its procaine salt form, and maintains effective blood concentrations for about 72 hours. It is rapidly excreted unchanged in the urine (over 80%).

A large portion of parenterally administered dihydrostreptomycin is excreted unchanged via the kidneys. The remaining portion accumulates in the renal cortex, showing a prolonged elimination process.

 

Indications / Uses

SHOTAPEN L.A. is used in cattle and dogs (both young and adult) for the treatment of respiratory, digestive, and urogenital infections caused by penicillin- and dihydrostreptomycin-sensitive pathogens, septicemias, secondary bacterial infections accompanying viral infections, and other soft tissue infections.

It is primarily used to support local treatment in cases of infectious pneumonia, actinomycosis, leptospirosis, umbilical infections, as well as mastitis and metritis.

 

Dosage and Administration

SHOTAPEN L.A. should be administered intramuscularly in cattle and intramuscularly or subcutaneously in dogs. It should not be administered intravenously. Before use, the bottle should be shaken to ensure the suspension is homogeneous.

Unless otherwise recommended by a veterinarian:

• In cattle: Administer 10 ml/100 kg body weight intramuscularly once or twice at a 72-hour interval, which provides 13.1 mg benzylpenicillin and 16.4 mg dihydrostreptomycin per kg body weight.

• In dogs: Administer 1–2 ml/25 kg body weight intramuscularly or subcutaneously once or twice at a 72-hour interval, which provides 5.3–10.6 mg benzylpenicillin and 6.7–13.1 mg dihydrostreptomycin per kg body weight.

To ensure the correct dosage, the animal's live weight should be accurately determined. During administration, aseptic and antiseptic procedures should be followed, and repeated applications to the same injection site should be avoided.

 

Withdrawal Period

• For cattle raised for meat: Do not send for slaughter within 77 days after the last treatment.

• For milk in cows: Do not use milk obtained from treated cows for human consumption within 8 days (16 milkings) after the last treatment. Due to the long withdrawal period for milk residues, it is not recommended to use in cows that produce milk for human consumption.